Comparison of Continuous Intravenous Lidocaine Infusion Versus ESP Block for Rib Fracture Analgesia
Launched by STANFORD UNIVERSITY · Jan 11, 2021
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of managing pain for patients with acute traumatic rib fractures. The researchers want to compare a newer treatment called the erector spinae plane block (ESPB) with the current standard treatment, which involves a continuous intravenous (IV) lidocaine infusion. The goal is to see which method provides better pain relief and helps patients breathe easier after their injuries.
To be eligible for the trial, participants must be adults admitted to Stanford Health Care with at least two rib fractures. However, those who are unstable, on mechanical ventilation, or have other serious health issues, like certain heart conditions, will not be able to join. If you participate, you can expect to receive one of the two pain management treatments and be monitored for your pain levels, breathing ability, and overall recovery. This study aims to improve pain management and enhance the quality of care for patients with rib fractures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - All adult patients admitted to Stanford Health Care with two or more acute traumatic rib fractures.
- Exclusion Criteria:
- • Hemodynamically instability,
- • Mechanical ventilation,
- • Polytrauma (defined as bone or organ injury outside the thorax),
- • Pregnancy,
- • Incarceration
- • Local anesthetic allergy or contraindications to lidocaine (Stokes-Adams syndrome, Wolff-Parkinson-White syndrome, or severe degrees of sinoatrial, atrioventricular, or intraventricular block)
- • Chronic opioid use.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials